Real-World Multiple Myeloma Patient Experience By Frailty Status: Symptom Burden, Physical Function, Quality of Life, and Treatment Bother Captured from Electronic Patient-Reported Outcomes (ePROs)

Speaker(s)

Coombs N1, Beamon E2, Rusli E3, Wujcik D4, Galaznik A4, Jamy O5
1Piedmont Research Strategies, Billings, MT, USA, 2Piedmont Research Strategies, Greenville, NC, USA, 3Carevive Systems, Inc, Newton, MA, USA, 4Carevive Systems, Inc, Boston, MA, USA, 5University of Alabama Birmingham, Birmingham, AL, USA

Presentation Documents

OBJECTIVES: Evidence suggests the value of frailty status when deciding on treatments in Multiple Myeloma (MM) practice. ePROs enable the capture of patient experience related to frailty and outcomes. This study aims to explore symptom burden, physical function, quality of life, and treatment bother collected from ePROs by frailty status.

METHODS: Patients with MM enrolled in Carevive PROmPT®, a remote symptom monitoring platform, between 9/1/2020 and 3/10/2023 were included. Baseline frailty status was ascertained from Carevive’s modified Geriatric Assessment (mGA), the Cancer and Aging Resilience Evaluation (CARE) geriatric survey, and patient-reported functional status. Outcomes were described using the validated tools: PRO-CTCAE for symptoms, PROMIS 4a for physical function, global health items from EORTC QLQ-C30 for quality of life, and FACT GP5 for treatment bother. Results were stratified by frailty status (Fit, Intermediate, Frail).

RESULTS: Of 151 patients included, frailty status was successfully classified for 97% of patients and 99% of patients with 12+ weeks of follow-up. Most patients were Fit (63%), 29% were Intermediate, and 8% were Frail. Median age was 66, 44% were females, 75% were white, and 56% had at least one comorbidity. The most frequently reported symptoms were general pain (23%), numbness and tingling (23%), and fatigue (21%). Symptom burden was considerably lower for Fit (16%) and Intermediate (16%) patients at the start of their treatment compared to Frail patients (25%). On average, physical function was two-fold higher for fit patients compared to frail patients. Treatment bother and quality of life were comparable over time across all levels of frailty. However, on average, frail patients began treatment at a lower level of quality of life.

CONCLUSIONS: Findings suggest there may be functional differences in the overall patient experience at different levels of frailty in MM. This further underscores the importance of capturing frailty status in oncology care.

Code

PCR146

Topic

Clinical Outcomes, Patient-Centered Research

Topic Subcategory

Clinical Outcomes Assessment, Patient Engagement, Patient-reported Outcomes & Quality of Life Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology